Cargando…
The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients
BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 separated pulmonary function from combined assessment. We aimed to analyze the characteristics of airflow limitation and future exacerbations in different GOLD groups of chronic obstructive pulmonary disease (COPD) pa...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143960/ https://www.ncbi.nlm.nih.gov/pubmed/34040367 http://dx.doi.org/10.2147/COPD.S309267 |
_version_ | 1783696861079535616 |
---|---|
author | Song, Qing Zhao, Yi-Yang Zeng, Yu-Qin Liu, Cong Cheng, Wei Deng, Min-Hua Li, Xin Ma, Li-Bing Chen, Yan Cai, Shan Chen, Ping |
author_facet | Song, Qing Zhao, Yi-Yang Zeng, Yu-Qin Liu, Cong Cheng, Wei Deng, Min-Hua Li, Xin Ma, Li-Bing Chen, Yan Cai, Shan Chen, Ping |
author_sort | Song, Qing |
collection | PubMed |
description | BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 separated pulmonary function from combined assessment. We aimed to analyze the characteristics of airflow limitation and future exacerbations in different GOLD groups of chronic obstructive pulmonary disease (COPD) patients. METHODS: For this prospective observational study, stable COPD outpatients were enrolled and divided into Groups A, B, C and D based on GOLD 2017, and followed-up for 18 months. Data on demographics, pulmonary function, COPD assessment test (CAT), Clinical COPD Questionnaire (CCQ), modified Medical Research Council (mMRC), exacerbations, mortality and treatments were collected. A post-bronchodilator ratio of forced expiratory volume in one second to forced vital capacity <0.70 confirms the presence of airflow limitation. RESULTS: A total of 993 subjects were classified into Groups A (n = 170, 17.1%), B (n = 360, 36.3%), C (n = 122, 12.3%), and D (n = 341, 34.3%). There were significant differences in mMRC, CAT, CCQ, exacerbations and hospitalizations rates among the different groups (P < 0.001). Groups B and D had more severe airflow limitation than Groups A and C (P < 0.05). In the same groups with different severity of airflow limitation, the differences were mainly observed in body mass index, CAT, CCQ and treatment with long-acting muscarinic antagonist (LAMA) and LAMA + long-acting β2-agonist + inhaled corticosteroid (P < 0.05). After 18 months of follow-up, the exacerbations and hospitalizations rates were significantly different among different groups (P < 0.05). However, in the same groups with different airflow limitation severity, the mortality rates and number of exacerbations, hospitalizations and frequent exacerbators showed no differences. CONCLUSION: In the GOLD groups, different severity of airflow limitation had no impact on future exacerbations and mortality rate. It implies that pulmonary function is not a good indicator for predicting exacerbation. |
format | Online Article Text |
id | pubmed-8143960 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-81439602021-05-25 The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients Song, Qing Zhao, Yi-Yang Zeng, Yu-Qin Liu, Cong Cheng, Wei Deng, Min-Hua Li, Xin Ma, Li-Bing Chen, Yan Cai, Shan Chen, Ping Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 separated pulmonary function from combined assessment. We aimed to analyze the characteristics of airflow limitation and future exacerbations in different GOLD groups of chronic obstructive pulmonary disease (COPD) patients. METHODS: For this prospective observational study, stable COPD outpatients were enrolled and divided into Groups A, B, C and D based on GOLD 2017, and followed-up for 18 months. Data on demographics, pulmonary function, COPD assessment test (CAT), Clinical COPD Questionnaire (CCQ), modified Medical Research Council (mMRC), exacerbations, mortality and treatments were collected. A post-bronchodilator ratio of forced expiratory volume in one second to forced vital capacity <0.70 confirms the presence of airflow limitation. RESULTS: A total of 993 subjects were classified into Groups A (n = 170, 17.1%), B (n = 360, 36.3%), C (n = 122, 12.3%), and D (n = 341, 34.3%). There were significant differences in mMRC, CAT, CCQ, exacerbations and hospitalizations rates among the different groups (P < 0.001). Groups B and D had more severe airflow limitation than Groups A and C (P < 0.05). In the same groups with different severity of airflow limitation, the differences were mainly observed in body mass index, CAT, CCQ and treatment with long-acting muscarinic antagonist (LAMA) and LAMA + long-acting β2-agonist + inhaled corticosteroid (P < 0.05). After 18 months of follow-up, the exacerbations and hospitalizations rates were significantly different among different groups (P < 0.05). However, in the same groups with different airflow limitation severity, the mortality rates and number of exacerbations, hospitalizations and frequent exacerbators showed no differences. CONCLUSION: In the GOLD groups, different severity of airflow limitation had no impact on future exacerbations and mortality rate. It implies that pulmonary function is not a good indicator for predicting exacerbation. Dove 2021-05-20 /pmc/articles/PMC8143960/ /pubmed/34040367 http://dx.doi.org/10.2147/COPD.S309267 Text en © 2021 Song et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Song, Qing Zhao, Yi-Yang Zeng, Yu-Qin Liu, Cong Cheng, Wei Deng, Min-Hua Li, Xin Ma, Li-Bing Chen, Yan Cai, Shan Chen, Ping The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients |
title | The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients |
title_full | The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients |
title_fullStr | The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients |
title_full_unstemmed | The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients |
title_short | The Characteristics of Airflow Limitation and Future Exacerbations in Different GOLD Groups of COPD Patients |
title_sort | characteristics of airflow limitation and future exacerbations in different gold groups of copd patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143960/ https://www.ncbi.nlm.nih.gov/pubmed/34040367 http://dx.doi.org/10.2147/COPD.S309267 |
work_keys_str_mv | AT songqing thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT zhaoyiyang thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT zengyuqin thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT liucong thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT chengwei thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT dengminhua thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT lixin thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT malibing thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT chenyan thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT caishan thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT chenping thecharacteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT songqing characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT zhaoyiyang characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT zengyuqin characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT liucong characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT chengwei characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT dengminhua characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT lixin characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT malibing characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT chenyan characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT caishan characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients AT chenping characteristicsofairflowlimitationandfutureexacerbationsindifferentgoldgroupsofcopdpatients |